This content is machine translated Oncology Multidisciplinary and cross-indication – the latest trends The central task of the European Society for Medical Oncology (ESMO) is to improve the quality of cancer treatment, cancer prevention and diagnosis as well as palliative care and aftercare…
View Post 3 min This content is machine translated Multiple Myeloma Individualized treatment management on the rise The formation of brain metastases is a dreaded development, especially in lung cancer. There is also an increasing focus on gender-specific differences in medicine. Multiple myeloma also has variables that…
View Post 3 min This content is machine translated Advanced hormone-sensitive prostate cancer Sustained testosterone reduction without injections Since January 1, 2024, the oral GnRH antagonist Relugolix has been approved in Switzerland for the treatment of adults with advanced hormone-sensitive prostate cancer [1, 2]. This gives patients access…
View Post 4 min This content is machine translated Gastrointestinal oncology From the gastrointestinal tract to the bladder and back In Switzerland, over 4000 people are diagnosed with bowel cancer every year. It does not cause any symptoms for a long time, so early detection is particularly important. Another component…
View Post 2 min This content is machine translated Pancreatic Cancer Resection outcome and pCR rate improved Chemotherapy (CT) is the standard treatment for non-resectable, locally advanced pancreatic cancer. The CONKO-007 study investigated the role of sequential CT and chemoradiotherapy (CRT). The first results have now been…
View Post 3 min This content is machine translated Neurology Therapeutic revolutions in the focus of science The Swiss Neurological Society (SNS) has been organizing an annual conference on a regular basis for 113 years. Over the decades, the training event has reinvented itself time and again…
View Post 4 min This content is machine translated Chronic lymphocytic leukemia (CLL) One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹ The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of…
View Post 2 min This content is machine translated Study report: Primary cutaneous lymphomas Skin-directed or systemic therapy? Diffuse large B-cell lymphoma is the most common malignant tumor of the lymphatic system. The primary objective of a retrospective clinical study led by Charité-Universitätsmedizin Berlin was to compare systemic…
View Post 11 min This content is machine translated Esophagus Therapy of esophageal carcinoma – an overview Esophageal carcinomas are comparatively rare tumors and account for approximately 1% of all malignancies worldwide. Based on their location, a distinction is made between cervical and intrathoracic tumors. Histologically, they… CME-Test
View Post 4 min This content is machine translated Risk stratification for Barrett's esophagus Pathology test beats human experts Low-grade dysplasia is associated with an increased risk of progression in Barrett’s esophagus, but the diagnosis of LGD is limited by considerable interobserver variability. Several studies have shown that the…
View Post 2 min This content is machine translated SCLC Small cell lung cancer in everyday therapy – an update Small cell lung carcinomas must be treated quickly – they usually grow rapidly and form metastases early on. The diagnosis is therefore often only made at an advanced stage. Lung…
